Even considering the above-mentioned flaws of these studies, it could be sound to hypothesize that a promising target for AD treatment could be searched for within the CX3CL1 signalling pathway and, generally, among molecules influencing microglia phenotypes. This evidence concerns the gene CX3CL1 and Alzheimer disease.